Keyword search (3,448 papers available)


Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia.

Author(s): DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E...

To determine the extent of metabotropic glutamate receptor type 5 (mGluR5) network abnormalities associated with focal cortical dysplasia (FCD), we performed graph theoretical analysis of [11C]ABP6...

Article GUID: 33401137
Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment

Author(s): Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G,...

INTRODUCTION: Abnormal brain amyloid beta (Aβ) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown...

Article GUID: 32582834
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Author(s): Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Les...

Nat Commun. 2019 Sep 17;10(1):4227 Authors: Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, ...

Article GUID: 31530809
Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.

Author(s): Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s ...

Eur J Nucl Med Mol Imaging. 2018 06;45(6):1021-1030 Authors: Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheim...

Article GUID: 29396637
Title:Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
Authors:Pascoal TA,  Therriault J,  Mathotaarachchi S,  Kang MS,  Shin M,  Benedet AL,  Chamoun M,  Tissot C,  Lussier F,  Mohaddes S,  Soucy JP,  Massarweh G,  Gauthier S,  Rosa-Neto P, 
Link:https://pubmed.ncbi.nlm.nih.gov/32582834/?utm_source=MS-Office&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1deGMjvjVspk9gsE
DOI:10.1002/dad2.12037
Category:
PMID:32582834
Dept Affiliation: PERFORM
1 Translational Neuroimaging Laboratory Alzheimer's Disease Research Unit The McGill University Research Centre for Studies in Aging McGill University Montreal Quebec Canada.
2 Department of Neurology and Neurosurgery McGill University Montreal Quebec Canada.
3 Montreal Neurological Institute Montreal Quebec Canada.
4 PERFORM Centre Concordia University Montreal Quebec Canada.

Description:

INTRODUCTION: Abnormal brain amyloid beta (Aß) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown whether the assessment of the topographical distribution of Aß pathology can provide additional information to identify, among global Aß positive individuals, those destined for dementia.